sulpiride has been researched along with Anochlesia in 40 studies
Sulpiride: A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed)
sulpiride : A member of the class of benzamides obtained from formal condensation between the carboxy group of 2-methoxy-5-sulfamoylbenzoic acid and the primary amino group of (1-ethylpyrrolidin-2-yl)methylamine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The induction of catalepsy in animal models is usually seen as an indicator of the propensity to induce extrapyramidal side effects in patients." | 2.42 | Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality. ( Möller, HJ, 2003) |
| " We found that RG-15 showed a good oral bioavailability (54%) and high brain levels (approx." | 1.35 | Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15. ( Agai Csongor, E; Domány, G; Elekes, O; Gémesi, LI; Gyertyán, I; Kapás, M; Kedves, R; Kiss, B; Laszy, J; Pásztor, G; Sághy, K; Szombathelyi, Z; Zájer-Balázs, M, 2008) |
| "In contrast, MS-377 did not affect the catalepsy induction by these drugs." | 1.31 | Effects of sigma(1) receptor ligand MS-377 on D(2) antagonists-induced behaviors. ( Horikomi, K; Karasawa, J; Takagi, K; Takahashi, S, 2002) |
| "The bar test was used to evaluate the catalepsy induced by each drug." | 1.31 | Effect of the amisulpride isomers on rat catalepsy. ( Bartholini, F; Casti, P; Gessa, G; Marchese, G; Pani, L; Ruiu, S; Saba, P, 2002) |
| "At low doses (+/-)-3b does not induce catalepsy, showing atypical antipsychotic properties similar to those of olanzapine." | 1.30 | New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure. ( Bechelli, S; Cagnotto, A; Campiani, G; Ciani, SM; de Boer, P; Fiorini, I; Garofalo, A; Liao, Y; Mennini, T; Nacci, V; Tepper, PG; Wikström, H, 1998) |
| "When treated with haloperidol, RIIbeta mutant mice fail to induce either c-fos or neurotensin mRNA and the acute cataleptic response is blocked." | 1.30 | Loss of haloperidol induced gene expression and catalepsy in protein kinase A-deficient mice. ( Adams, MR; Brandon, EP; Chartoff, EH; Dorsa, DM; Idzerda, RL; McKnight, GS, 1997) |
| "Prominent catalepsy, otherwise consistently seen in the mice treated with haloperidol (0." | 1.30 | Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats. ( Buljat, G; Dodig, G; Jelovac, N; Marovic, A; Miklic, P; Mise, S; Perovic, D; Petek, M; Prkacin, I; Rucman, R; Seiwerth, S; Sikiric, P; Turkovic, B, 1999) |
| "During the induction of catalepsy, the intensity was the strongest at 4." | 1.28 | Comparative studies of sulpiride and classical neuroleptics on induction of catalepsy, locomotor activity, and brain dopamine metabolism in mice. ( Fujiwara, H, 1992) |
| "1." | 1.28 | Blockade of both D-1 and D-2 dopamine receptors may induce catalepsy in mice. ( Habibi-Moini, S; Zarrindast, MR, 1991) |
| "Severe vomiting was evoked by Apo in dogs, but not by Eph even when lethal dose (20 mg." | 1.28 | [Comparison of central stimulating effects between ephedrine and apomorphine]. ( Li, BH; Li, Q, 1991) |
| "Narcolepsy is a sleep disorder characterized by abnormal manifestations of rapid-eye-movement (REM) sleep and excessive daytime sleepiness." | 1.28 | Dopamine D2 mechanisms in canine narcolepsy. ( Arrigoni, J; Dement, WC; Guilleminault, C; Mignot, E; Miller, JD; Nishino, S; Valtier, D, 1991) |
| "It is concluded that (1) the catalepsy induced by systemic administration of haloperidol seems to result from the action of this drug on both the ventro-rostral striatum and the nucleus accumbens, (2) both D1 and D2 dopamine receptors in the ventro-rostral striatum are involved in the cataleptogenic action of neuroleptics, and (3) in the nucleus accumbens, only D1 dopamine receptors seem to play an important role in this phenomenon." | 1.28 | Striatal and nucleus accumbens D1/D2 dopamine receptors in neuroleptic catalepsy. ( Karcz, M; Ossowska, K; Wardas, J; Wolfarth, S, 1990) |
| "The neuroleptic-induced catalepsy was reversed by the classical anti-parkinsonian agent L-DOPA and by agents that function through dopamine systems such as d- and methamphetamine and the direct D2 receptor agonist quinpirole." | 1.28 | Neuroleptic-induced catalepsy as a model of Parkinson's disease. I. Effect of dopaminergic agents. ( Close, SP; Elliott, PJ; Hayes, AG; Marriott, AS; Walsh, DM, 1990) |
| "Remoxipride was shown to be a selective dopamine D2 receptor antagonist since it displaced [3H]spiperone (IC50 = 1570 nM) but not [3H]flupentixol (IC50 greater than 100 000 nM) in rat striatum, and did not inhibit striatal DA-sensitive adenylate cyclase in vitro (IC50 greater than 100 000 nM)." | 1.27 | Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain. ( Angeby, K; Florvall, L; Hall, H; Köhler, C; Lindbom, LO; Magnusson, O; Ogren, SO, 1984) |
| "Similarly, catalepsy induced by (-)-sulpiride (40 mg/kg, i." | 1.27 | Influence of (-)-sulpiride and YM-09151-2 on stereotyped behavior in chicks and catalepsy in rats. ( Wambebe, C, 1987) |
| "Prior to the induction of catalepsy and after recovery from it, mice display the entire range of typical apomorphine-induced behavior including sniffing, climbing, gnawing, and licking." | 1.27 | Simultaneous catalepsy and apomorphine-induced stereotypic behavior in mice. ( Randall, PK; Yurek, DM, 1985) |
| "Sulpiride was administered orally and intraventricularly, and the effects of sulpiride were compared to those of haloperidol and chlorpromazine administered through the same routes." | 1.26 | Dopamine receptor blocking activity of sulpiride in the central nervous system. ( Honda, F; Kato, R; Noguchi, H; Satoh, H; Satoh, Y; Shimomura, K; Uchida, S, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (35.00) | 18.7374 |
| 1990's | 21 (52.50) | 18.2507 |
| 2000's | 5 (12.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Iwanami, S | 1 |
| Takashima, M | 2 |
| Hirata, Y | 1 |
| Hasegawa, O | 1 |
| Usuda, S | 1 |
| Florvall, L | 2 |
| Ogren, SO | 4 |
| Campiani, G | 1 |
| Nacci, V | 1 |
| Bechelli, S | 1 |
| Ciani, SM | 1 |
| Garofalo, A | 1 |
| Fiorini, I | 1 |
| Wikström, H | 1 |
| de Boer, P | 1 |
| Liao, Y | 1 |
| Tepper, PG | 1 |
| Cagnotto, A | 1 |
| Mennini, T | 1 |
| Gyertyán, I | 1 |
| Sághy, K | 1 |
| Laszy, J | 1 |
| Elekes, O | 1 |
| Kedves, R | 1 |
| Gémesi, LI | 1 |
| Pásztor, G | 1 |
| Zájer-Balázs, M | 1 |
| Kapás, M | 1 |
| Agai Csongor, E | 1 |
| Domány, G | 1 |
| Kiss, B | 1 |
| Szombathelyi, Z | 1 |
| Karasawa, J | 1 |
| Takahashi, S | 2 |
| Takagi, K | 2 |
| Horikomi, K | 2 |
| Marchese, G | 1 |
| Bartholini, F | 1 |
| Ruiu, S | 1 |
| Casti, P | 1 |
| Saba, P | 1 |
| Gessa, G | 1 |
| Pani, L | 1 |
| Möller, HJ | 1 |
| Zetterström, T | 1 |
| Sharp, T | 1 |
| Ungerstedt, U | 1 |
| Worms, P | 1 |
| Köhler, C | 3 |
| Fuxe, K | 1 |
| Hall, H | 1 |
| Magnusson, O | 1 |
| Lindbom, LO | 1 |
| Angeby, K | 1 |
| Ossowska, K | 3 |
| Karcz-Kubicha, M | 1 |
| Wardas, J | 3 |
| Krezołek, A | 1 |
| Wolfarth, S | 3 |
| Maj, J | 1 |
| Rogóz, Z | 1 |
| Skuza, G | 1 |
| Kołodziejczyk, K | 1 |
| Horikawa, HP | 1 |
| Nakazato, T | 1 |
| Hikosaka, O | 1 |
| Adams, MR | 1 |
| Brandon, EP | 1 |
| Chartoff, EH | 1 |
| Idzerda, RL | 1 |
| Dorsa, DM | 1 |
| McKnight, GS | 1 |
| Hauber, W | 2 |
| Campbell, KM | 1 |
| McGrath, MJ | 1 |
| Burton, FH | 1 |
| Sonehara, K | 1 |
| Miwa, T | 1 |
| Mita, N | 1 |
| Nagase, H | 1 |
| Iizuka, K | 1 |
| Sakai, K | 1 |
| Jelovac, N | 1 |
| Sikiric, P | 1 |
| Rucman, R | 1 |
| Petek, M | 1 |
| Marovic, A | 1 |
| Perovic, D | 1 |
| Seiwerth, S | 1 |
| Mise, S | 1 |
| Turkovic, B | 1 |
| Dodig, G | 1 |
| Miklic, P | 1 |
| Buljat, G | 1 |
| Prkacin, I | 1 |
| Asmakova, LS | 1 |
| Kalinina, TS | 1 |
| Ostrovskaya, RU | 1 |
| Gudasheva, TA | 1 |
| Zaitseva, NI | 1 |
| Bondarenko, NA | 1 |
| Voronina, TA | 1 |
| Seredenin, SB | 1 |
| Zarrindast, MR | 2 |
| Haeri-Zadeh, F | 1 |
| Zarghi, A | 1 |
| Lahiji, P | 1 |
| Neuscheler, P | 1 |
| Nagel, J | 1 |
| Müller, CE | 1 |
| Elliott, PN | 1 |
| Jenner, P | 1 |
| Huizing, G | 1 |
| Marsden, CD | 1 |
| Miller, R | 1 |
| Honda, F | 1 |
| Satoh, Y | 1 |
| Shimomura, K | 1 |
| Satoh, H | 1 |
| Noguchi, H | 1 |
| Uchida, S | 1 |
| Kato, R | 1 |
| Haglund, L | 1 |
| Angeby, T | 1 |
| Honma, T | 1 |
| Fukushima, H | 1 |
| Costall, B | 1 |
| Naylor, RJ | 1 |
| Fujiwara, H | 1 |
| Motohashi, N | 1 |
| Mataga, N | 1 |
| Nishikawa, T | 1 |
| Ogawa, A | 1 |
| Watanabe, S | 1 |
| Toru, M | 1 |
| Habibi-Moini, S | 1 |
| Schmidt, C | 1 |
| Gobaille, S | 1 |
| Hechler, V | 1 |
| Schmitt, M | 1 |
| Bourguignon, JJ | 1 |
| Maitre, M | 1 |
| Li, Q | 1 |
| Li, BH | 1 |
| Nishino, S | 1 |
| Arrigoni, J | 1 |
| Valtier, D | 1 |
| Miller, JD | 1 |
| Guilleminault, C | 1 |
| Dement, WC | 1 |
| Mignot, E | 1 |
| Karcz, M | 1 |
| Elliott, PJ | 2 |
| Close, SP | 2 |
| Walsh, DM | 2 |
| Hayes, AG | 2 |
| Marriott, AS | 2 |
| Golembiowska, K | 1 |
| Wambebe, C | 1 |
| Puglisi-Allegra, S | 1 |
| Cabib, S | 1 |
| Yurek, DM | 1 |
| Randall, PK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparative Efficacy and Safety of Low Dose Amisulpride Vs Olanzapine-Fluoxetine Combination in the Treatment of Post Schizophrenic Depression: A Randomized Controlled Trial[NCT04876521] | Phase 4 | 60 participants (Anticipated) | Interventional | 2021-05-04 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for sulpiride and Anochlesia
| Article | Year |
|---|---|
Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality.
Topics: Amisulpride; Animals; Antipsychotic Agents; Catalepsy; Dissociative Disorders; Dopamine Antagonists; | 2003 |
39 other studies available for sulpiride and Anochlesia
| Article | Year |
|---|---|
Synthesis and neuroleptic activity of benzamides. Cis-N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-(methylamino)benzamide and related compounds.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Benzamides; Catalepsy; Humans; Rats; Stereotyped | 1981 |
Potential neuroleptic agents. 2,6-Dialkoxybenzamide derivatives with potent dopamine receptor blocking activities.
Topics: Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Benzamides; Catalepsy; Chemical Phenom | 1982 |
New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antipsychotic Agents; Brain; Catalepsy; Dopamine; Dopamine | 1998 |
Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15.
Topics: Amisulpride; Animals; Antipsychotic Agents; Avoidance Learning; Benzodiazepines; Biological Availabi | 2008 |
Effects of sigma(1) receptor ligand MS-377 on D(2) antagonists-induced behaviors.
Topics: Amisulpride; Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Catalepsy; Dopamine Agoni | 2002 |
Effect of the amisulpride isomers on rat catalepsy.
Topics: Amisulpride; Analysis of Variance; Animals; Brain; Catalepsy; Dose-Response Relationship, Drug; Male | 2002 |
Effect of neuroleptic drugs on striatal dopamine release and metabolism in the awake rat studied by intracerebral dialysis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antipsychotic Agents; Catalepsy; Corpus Striatum; Dialysis; | 1984 |
Behavioral pharmacology of the benzamides as compared to standard neuroleptics.
Topics: Amisulpride; Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Benzamides; Catalepsy; Hu | 1982 |
Studies on the mechanism of action of substituted benzamide drugs.
Topics: Animals; Antipsychotic Agents; Apomorphine; Benzamides; Brain; Catalepsy; Corpus Striatum; Humans; H | 1984 |
Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain.
Topics: Adenylyl Cyclases; Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Benzamides; Binding | 1984 |
Zona incerta-lateral hypothalamus as an output structure for impulses involved in neuroleptic drug-induced catalepsy.
Topics: Animals; Antipsychotic Agents; Bicuculline; Catalepsy; Corpus Striatum; Globus Pallidus; Hypothalami | 1993 |
The behavioural effects of pramipexole, a novel dopamine receptor agonist.
Topics: Animals; Antiparkinson Agents; Benzazepines; Benzothiazoles; Body Temperature; Catalepsy; Clozapine; | 1997 |
Duration of catalepsy correlates with increased intrastriatal sulpiride.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Catalepsy; Dopamine; Dopamine | 1997 |
Loss of haloperidol induced gene expression and catalepsy in protein kinase A-deficient mice.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Catalepsy; Corpus Striatum; Cyclic AMP-Dependent Pr | 1997 |
Blockade of subthalamic dopamine D1 receptors elicits akinesia in rats.
Topics: Animals; Benzazepines; Catalepsy; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Male; Rats | 1998 |
Differential response of cortical-limbic neuropotentiated compulsive mice to dopamine D1 and D2 receptor antagonists.
Topics: Animals; Behavior, Animal; Benzazepines; Catalepsy; Cerebral Cortex; Cholera Toxin; Compulsive Behav | 1999 |
Pharmacological profile of MS-377, a novel antipsychotic agent with selective affinity for sigma receptors.
Topics: Amisulpride; Animals; Antipsychotic Agents; Apomorphine; Catalepsy; Dopamine Agonists; Free Radical | 1999 |
Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats.
Topics: Animals; Anti-Ulcer Agents; Antipsychotic Agents; Catalepsy; Clozapine; Dopamine Antagonists; Dose-R | 1999 |
Comparison of antipsychotic activity and discriminative stimulus effects of the novel acylprolyltyrosine containing compound, GZR-123, and sulpiride.
Topics: Animals; Antipsychotic Agents; Apomorphine; Catalepsy; Discrimination, Psychological; Dopamine Agent | 1999 |
Nicotine potentiates sulpiride-induced catalepsy in mice.
Topics: Animals; Antipsychotic Agents; Atropine; Catalepsy; Dose-Response Relationship, Drug; Drug Synergism | 1998 |
Catalepsy induced by a blockade of dopamine D1 or D2 receptors was reversed by a concomitant blockade of adenosine A(2A) receptors in the caudate-putamen of rats.
Topics: Adenosine; Animals; Benzazepines; Catalepsy; Caudate Nucleus; Dopamine Antagonists; Drug Interaction | 2001 |
Substituted benzamides as cerebral dopamine antagonists in rodents.
Topics: Adenylyl Cyclases; Animals; Apomorphine; Behavior, Animal; Benzamides; Brain; Catalepsy; Corpus Stri | 1977 |
Dopamine receptor blocking activity of sulpiride in the central nervous system.
Topics: Administration, Oral; Animals; Apomorphine; Behavior, Animal; Brain; Catalepsy; Cerebral Ventricles; | 1977 |
Regional displacement by sulpiride of [3H]spiperone binding in vivo. Biochemical and behavioural evidence for a preferential action of limbic and nigral dopamine receptors.
Topics: Animals; Apomorphine; Binding, Competitive; Brain; Butyrophenones; Catalepsy; Haloperidol; Humans; M | 1979 |
Correlation between catalepsy and dopamine decrease in the rat striatum induced by neuroleptics.
Topics: Animals; Butyrophenones; Catalepsy; Chlorpromazine; Clozapine; Corpus Striatum; Dopamine; Dose-Respo | 1976 |
Detection of the nueroleptic properties of clozapine, sulpiride and thioridazine.
Topics: Animals; Apomorphine; Behavior, Animal; Catalepsy; Clozapine; Dextroamphetamine; Dibenzazepines; Dos | 1975 |
Comparative studies of sulpiride and classical neuroleptics on induction of catalepsy, locomotor activity, and brain dopamine metabolism in mice.
Topics: Animals; Antipsychotic Agents; Brain Chemistry; Catalepsy; Dopamine; Haloperidol; Male; Mice; Mice, | 1992 |
Effects of sulpiride and oxypertine on the dopaminergic system in the rat striatum.
Topics: Animals; Brain; Catalepsy; Corpus Striatum; Injections, Intraventricular; Male; Piperazines; Rats; R | 1992 |
Blockade of both D-1 and D-2 dopamine receptors may induce catalepsy in mice.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Catalepsy; Dopami | 1991 |
Anti-sedative and anti-cataleptic properties of NCS-382, a gamma-hydroxybutyrate receptor antagonist.
Topics: Animals; Anticonvulsants; Benzocycloheptenes; Catalepsy; Dose-Response Relationship, Drug; Haloperid | 1991 |
[Comparison of central stimulating effects between ephedrine and apomorphine].
Topics: Animals; Apomorphine; Blepharoptosis; Catalepsy; Ephedrine; Haloperidol; Male; Mice; Motor Activity; | 1991 |
Dopamine D2 mechanisms in canine narcolepsy.
Topics: Animals; Catalepsy; Dogs; Dopamine Antagonists; Ergolines; Motor Activity; Narcolepsy; Quinpirole; R | 1991 |
Striatal and nucleus accumbens D1/D2 dopamine receptors in neuroleptic catalepsy.
Topics: Animals; Antipsychotic Agents; Benzazepines; Catalepsy; Corpus Striatum; Dose-Response Relationship, | 1990 |
Neuroleptic-induced catalepsy as a model of Parkinson's disease. I. Effect of dopaminergic agents.
Topics: Animals; Antipsychotic Agents; Catalepsy; Disease Models, Animal; Dopamine; Dose-Response Relationsh | 1990 |
Neuroleptic-induced catalepsy as a model of Parkinson's disease. II. Effect of glutamate antagonists.
Topics: Animals; Antipsychotic Agents; Catalepsy; Disease Models, Animal; Dizocilpine Maleate; Fluphenazine; | 1990 |
Lateral hypothalamus-zona incerta region as an output station for the catalepsy induced by the blockade of striatal D1 and D2 dopamine receptors.
Topics: Animals; Benzazepines; Bicuculline; Catalepsy; Corpus Striatum; Dose-Response Relationship, Drug; Hy | 1990 |
Influence of (-)-sulpiride and YM-09151-2 on stereotyped behavior in chicks and catalepsy in rats.
Topics: Aging; Animals; Antipsychotic Agents; Benzamides; Catalepsy; Chickens; Dextroamphetamine; Fenclonine | 1987 |
The D2 dopamine receptor agonist LY171555 induces catalepsy in the mouse.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Appetite Depressants; Benzazepi | 1988 |
Simultaneous catalepsy and apomorphine-induced stereotypic behavior in mice.
Topics: Animals; Apomorphine; Catalepsy; Chlorpromazine; Domperidone; Drug Interactions; Haloperidol; Inject | 1985 |